
Christopher M Bunce

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9136886/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells. Bioscience Reports, 2021, 41, .	2.4	5
2	Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers. Contemporary Clinical Trials Communications, 2019, 14, 100361.	1.1	6
3	The Role of Eif6 in Skeletal Muscle Homeostasis Revealed by Endurance Training Co-expression Networks. Cell Reports, 2017, 21, 1507-1520.	6.4	22
4	Tracerâ€Based Metabolic NMRâ€Based Flux Analysis in a Leukaemia Cell Line. ChemPlusChem, 2016, 81, 453-459.	2.8	15
5	Malonate as a ROS product is associated with pyruvate carboxylase activity in acute myeloid leukaemia cells. Cancer & Metabolism, 2016, 4, 15.	5.0	20
6	Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 47-55.	2.5	15
7	The case for extracellular Nm23-H1 as a driver of acute myeloid leukaemia (AML) progression. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 225-233.	3.0	9
8	Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas. Leukemia and Lymphoma, 2015, 56, 1079-1087.	1.3	5
9	Metabolic Fluxes in Cancer Metabolism. , 2015, , 315-348.		5
10	Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic <scp>B</scp> urkitt lymphoma in <scp>M</scp> alawi; an open″abel, singleâ€arm, phase 2 study (ISRCTN34303497). British Journal of Haematology, 2014, 164, 888-890.	2.5	13
11	Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease. PLoS ONE, 2013, 8, e56422.	2.5	56
12	Hypoxia Triggers Major Metabolic Changes in AML Cells without Altering Indomethacin-Induced TCA Cycle Deregulation. ACS Chemical Biology, 2011, 6, 169-175.	3.4	31
13	The Haematopoietic Stem Cell Niche: New Insights into the Mechanisms Regulating Haematopoietic Stem Cell Behaviour. Stem Cells International, 2011, 2011, 1-10.	2.5	36
14	Nm23-H1 Indirectly Promotes the Survival of Acute Myeloid Leukemia Blast Cells by Binding to More Mature Components of the Leukemic Clone. Cancer Research, 2011, 71, 1177-1186.	0.9	18
15	Elevated NCOR1 disrupts PPARα/γ signaling in prostate cancer and forms a targetable epigenetic lesion. Carcinogenesis, 2010, 31, 1650-1660.	2.8	56
16	Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell Lines. PLoS ONE, 2009, 4, e4251.	2.5	101
17	Analysis of the role of COP9 Signalosome (CSN) subunits in K562; the first link between CSN and autophagy. BMC Cell Biology, 2009, 10, 31.	3.0	20
18	Where now in elderly AML?. British Journal of Haematology, 2009, 145, 333-333.	2.5	1

CHRISTOPHER M BUNCE

#	Article	IF	CITATIONS
19	Characterization of Two Novel Aldo–Keto Reductases from Arabidopsis: Expression Patterns, Broad Substrate Specificity, and an Open Active-Site Structure Suggest a Role in Toxicant Metabolism Following Stress. Journal of Molecular Biology, 2009, 392, 465-480.	4.2	123
20	Evaluation of Solvent Accessibility Epitopes for Different Dehydrogenase Inhibitors. ChemMedChem, 2008, 3, 1371-1376.	3.2	16
21	Optimized metabolite extraction from blood serum for 1H nuclear magnetic resonance spectroscopy. Analytical Biochemistry, 2008, 377, 16-23.	2.4	164
22	PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood, 2005, 106, 1362-1368.	1.4	127
23	All-transRetinoic Acid Increases Transgene Expression in MSCV-Transduced Cells, via a Mechanism That Is Retinoid Receptor Dependent but Independent of Cellular Differentiation. Human Gene Therapy, 2005, 16, 132-138.	2.7	0
24	The serotonin transporter (SLC6A4) is present in B ell clones of diverse malignant origin: probing a potential antitumor target for psychotropics. FASEB Journal, 2005, 19, 1187-1189.	0.5	77
25	Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin. Cancer Research, 2004, 64, 1802-1810.	0.9	106
26	Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood, 2003, 101, 3212-3219.	1.4	158
27	The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Research, 2003, 63, 505-12.	0.9	117
28	Estrone potentiates myeloid cell differentiation. Experimental Hematology, 1999, 27, 451-460.	0.4	24
29	Bistratene A Induces a Microtubule-Dependent Block in Cytokinesis and Altered Stathmin Expression in HL60 Cells. Biochemical and Biophysical Research Communications, 1999, 260, 80-88.	2.1	14
30	Triiodothyronine blocks potentiation of HL60 monocyte differentiation by anti-inflammatory agents and by steroids and induces apoptosis of all-trans retinoic acid "primed―cells. Leukemia Research, 1997, 21, 623-634.	0.8	5
31	Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family. Biochimica Et Biophysica Acta - Molecular Cell Research, 1996, 1311, 189-198.	4.1	45
32	Growth of single HL60 cells in liquid culture: Analysis of the influences of differentiative agents. Leukemia Research, 1996, 20, 821-829.	0.8	10
33	Expression of a nuclear envelope protein recognized by the monoclonal antibody BU31 in lung tumours: Relationship to Ki-67 antigen expression. Journal of Pathology, 1994, 173, 89-96.	4.5	6
34	Intracellular concentrations of inositol, glycerophosphoinositol and inositol pentakisphosphate increase during haemopoietic cell differentiation. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1222, 101-108.	4.1	34
35	1α,25-Dihydroxyvitamin D3 promotes monocytopoiesis and suppresses granulocytopoiesis in cultures of normal human myeloid blast cells. Journal of Leukocyte Biology, 1994, 56, 124-132.	3.3	17
36	Inositol Lipids and Phosphates in the Proliferation and Differentiation of Lymphocytes and Myeloid Cells. Novartis Foundation Symposium, 1992, 164, 2-16.	1.1	3

Christopher M Bunce

#	Article	IF	CITATIONS
37	Changes in inositol transport during DMSO-induced differentiation of HL60 cells towards neutrophils. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1091, 158-164.	4.1	10
38	Protein phosphorylation events and changes in inositol metabolism during HL60 cell differentiation. Biochemical Society Transactions, 1991, 19, 315-320.	3.4	3
39	Models of haemopoiesis. Leukemia Research, 1990, 14, 495-499.	0.8	7
40	Phorbol myristate acetate treatment of normal human myeloid blast cells promotes monopoiesis and inhibits granulopoiesis. Leukemia Research, 1990, 14, 1007-1017.	0.8	8
41	The development of cell lineages: A sequential model. Differentiation, 1988, 39, 83-89.	1.9	28
42	A rapid procedure for isolating hemopoietic cell nuclei. Analytical Biochemistry, 1988, 175, 67-73.	2.4	44
43	Cathepsin B synthesis by the HL60 promyelocytic cell line: effects of stimulating agents and anti-inflammatory compounds. Biochimica Et Biophysica Acta - Molecular Cell Research, 1986, 887, 283-290.	4.1	14
44	Expression of a 215,000-dalton nuclear envelope protein decreases during cell maturation. Leukemia Research, 1986, 10, 1175-1182.	0.8	3
45	Variant cell lines from the human promyelocyte line HL60. Leukemia Research, 1982, 6, 491-498.	0.8	28